A polymorph change discovered after a stability batch has shipped is no longer just a formulation headache — it can trigger a deficiency letter, delay an IND, or unravel a patent position. Regulators increasingly expect sponsors to demonstrate control over the solid form of a drug substance, not simply characterize it retrospectively. For teams running lean CMC programs, that expectation now arrives earlier in development and carries heavier consequences than it did a decade ago.
The Shift: From Lab Observation to Regulatory Expectation
For a long time, solid-state characterization was treated as a technical exercise that happened somewhere between process chemistry and formulation — useful, but rarely decisive. That framing is changing. Polymorphism, salt form, and amorphous stability are increasingly assessed as part of the overall risk profile of a drug substance, alongside impurity control and process robustness.
This is not a hypothetical shift. ICH Q6A has required a documented rationale for polymorph control in new drug substance specifications for years, and agencies have become more consistent in asking sponsors to justify why a given form was selected, how it is monitored, and what would happen if it changed under storage or processing stress. The question is no longer whether solid form matters; it is whether a sponsor can prove, with data, that they understand it.
What Is Driving the Change
Several forces are converging to raise the bar on solid-state evidence.
First, the pipeline itself has become more demanding. Oncology, antibody-drug conjugate payloads, and CNS-active controlled substances — all areas of active growth — involve complex, often high-potency small molecules with narrower therapeutic windows and less forgiving manufacturing tolerances. Second, analytical expectations have broadened: the recent revision of ICH Q2 extends validation principles beyond classical chromatography to the broader set of techniques — XRPD, solid-state NMR, thermal analysis — that solid-state work depends on. Third, commercial and legal pressure has not eased; crystal form remains one of the most contested grounds in pharmaceutical patent disputes, which means a weak solid-form dossier is also a weak IP position.
- Higher proportion of complex, high-potency modalities entering the clinic
- Broader regulatory scope for analytical method validation
- Continued use of solid-form claims as a patent strategy
- Growing share of development work run by resource-constrained emerging biotech
A Case the Industry Still Studies
The pharmaceutical industry’s most frequently cited cautionary example remains the appearance of an unexpected, more thermodynamically stable crystal form of a protease inhibitor in the late 1990s, which disrupted manufacturing and led to a product reformulation. The episode is decades old, but it is still taught because the underlying mechanism has not gone away: a form that is stable and well-behaved at small scale can transform under different crystallization conditions, storage environments, or formulation stress at larger scale.
What has changed since then is not the chemistry — it is the expectation that sponsors anticipate this risk proactively rather than discover it reactively. A polymorph screen run late, or run narrowly, no longer just risks a manufacturing deviation; it risks a regulatory question that is harder to answer after the fact than before it.
Who Is Most Exposed
The exposure is not evenly distributed across the industry.
Emerging biotech companies — now responsible for the majority of clinical trial starts globally — often run CMC programs with small internal teams and limited solid-state expertise in-house. Mid-size pharma companies scaling a molecule from clinical to commercial manufacturing face a different risk: a form that behaved well at kilogram scale may not behave identically at hundreds of kilograms. Large pharma R&D organizations managing portfolios that increasingly include HPAPIs and controlled substances face a compliance and containment burden that compounds the analytical one.
- Emerging biotech: limited internal solid-state capability, compressed timelines
- Mid-size pharma: scale-up risk between clinical and commercial batches
- Large pharma: portfolio complexity across high-potency and controlled compounds
Separating Established Fact From Reasonable Expectation
It is worth being precise about what is confirmed guidance and what is industry trajectory.
What is established: ICH Q6A has long required a documented control strategy for polymorphism in new drug substance specifications, and ICH Q2(R2) has formally broadened the scope of validated analytical procedures. What is a reasonable, widely shared expectation rather than a published rule: that regulatory reviewers will continue to scrutinize solid-state data packages more closely as molecules become more potent and formulations become more complex, and that this scrutiny will extend further into amorphous dispersions and co-crystal systems as those technologies move from niche to mainstream. Sponsors should plan for the second category even though it is not yet codified line by line.
What This Means for CMC and Outsourcing Strategy
The practical response is not more testing for its own sake; it is testing that is placed earlier and designed to answer the right question at the right phase.
A phase-appropriate solid-form strategy typically starts with a reasonably broad polymorph and salt screen before the lead form is locked, followed by targeted stability and stress studies that reflect realistic manufacturing and storage conditions, and validated, audit-ready methods once the program moves toward GMP. Skipping steps to save time early often reappears later as a request for additional data from a regulator, or as a scale-up surprise that is far more expensive to resolve.
- Screen before locking the development form, not after
- Match stress conditions to realistic process and storage scenarios
- Validate analytical methods to the phase the molecule is actually in
- Document the rationale for form selection, not just the data
De-risking Through the Right Partnership
This is where a specialized CRO/CDMO partner changes the economics of the problem. PCL Research & Manufacturing works across the full solid-state arc — polymorph and salt screening, co-crystal discovery, stability screening, and solid-state characterization by XRPD, DSC, TGA, and solid-state NMR — inside FDA-inspected, AIFA GMP-certified facilities.
For programs involving high-potency compounds up to OEB5 or controlled substances requiring AIFA/DEA-authorized handling, that infrastructure is not a convenience; it is what makes the data defensible. Building this capability internally, particularly for emerging biotech and mid-size pharma teams, is rarely the fastest or most capital-efficient path, which is a central reason the broader CRO and HPAPI contract manufacturing markets are both expanding faster than the industry’s organic R&D headcount.
None of this means every molecule needs an exhaustive solid-form investigation — it means the investigation should be sized to the molecule’s risk and timed to precede the decisions it is meant to inform. If your team is weighing how much solid-state work is enough for your current phase, or how to handle a high-potency or controlled compound without building containment infrastructure from scratch, we would be glad to compare notes on where the real risk sits in your specific program.
